Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSUNAMI: Convalescent Plasma for Early Treatment of COVID-19 Pneumonia
NCT04393727Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- May 2020
- Primary completion
- Sep 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in COVID-19 pneumonia (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Need of invasive mechanical ventilation at 30 days. Started May 2020; status: terminated.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04393727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393727.